Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
filgrastim + prednisolone
- Development stage
- Phase 3
- Lead developer
- Amgen
- Modality
- Small Molecules, Recombinant Proteins and Enzymes
- Administration
- Subcutaneous, Intravenous, Oral
01
Overview
This is a combination of filgrastim, a granulocyte colony-stimulating factor (G-CSF) that stimulates neutrophil production, and prednisolone, a corticosteroid. Filgrastim is used to reduce the duration of neutropenia and neutropenia-related clinical sequelae in patients receiving myelosuppressive chemotherapy. Prednisolone is a corticosteroid with anti-inflammatory and immunosuppressive properties often included in chemotherapy regimens. This combination may be used in treatment protocols for conditions like Hodgkin's disease, where prednisolone is part of the chemotherapy regimen and filgrastim is used as supportive care.
02
Targets
Beyond the preview
Go deeper on filgrastim + prednisolone.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on filgrastim + prednisolone.